These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 39008106)
1. Cefepime/enmetazobactam (Exblifep) for complicated urinary tract infections. Med Lett Drugs Ther; 2024 Jul; 66(1707):117-118. PubMed ID: 39008106 [No Abstract] [Full Text] [Related]
2. Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial. Kaye KS; Belley A; Barth P; Lahlou O; Knechtle P; Motta P; Velicitat P JAMA; 2022 Oct; 328(13):1304-1314. PubMed ID: 36194218 [TBL] [Abstract][Full Text] [Related]
3. Treatment of infections caused by multidrug-resistant Gram-negative bacilli: A practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases. Meschiari M; Asquier-Khati A; Tiseo G; Luque-Paz D; Murri R; Boutoille D; Falcone M; Mussini C; Tattevin P; Int J Antimicrob Agents; 2024 Jul; 64(1):107186. PubMed ID: 38688353 [TBL] [Abstract][Full Text] [Related]
4. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. Bader MS; Loeb M; Leto D; Brooks AA Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743 [TBL] [Abstract][Full Text] [Related]
5. Meropenem/vaborbactam (Vabomere) for complicated urinary tract infection. Med Lett Drugs Ther; 2018 Jun; 60(1549):103-105. PubMed ID: 29913473 [No Abstract] [Full Text] [Related]
6. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa. Lasarte-Monterrubio C; Fraile-Ribot PA; Vázquez-Ucha JC; Cabot G; Guijarro-Sánchez P; Alonso-García I; Rumbo-Feal S; Galán-Sánchez F; Beceiro A; Arca-Suárez J; Oliver A; Bou G J Antimicrob Chemother; 2022 Sep; 77(10):2809-2815. PubMed ID: 35904000 [TBL] [Abstract][Full Text] [Related]
9. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019. Karlowsky JA; Lob SH; Khan A; Chen WT; Woo PCY; Seto WH; Ip M; Leung S; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451945 [No Abstract] [Full Text] [Related]
10. Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital. Weber C; Schultze T; Göttig S; Kessel J; Schröder A; Tietgen M; Besier S; Burbach T; Häussler S; Wichelhaus TA; Hack D; Kempf VAJ; Hogardt M Microbiol Spectr; 2022 Oct; 10(5):e0169722. PubMed ID: 36190424 [TBL] [Abstract][Full Text] [Related]
11. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909 [TBL] [Abstract][Full Text] [Related]
12. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections. Sader HS; Castanheira M; Duncan LR; Mendes RE Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144 [TBL] [Abstract][Full Text] [Related]
13. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199 [TBL] [Abstract][Full Text] [Related]
14. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021). Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Shortridge D; Castanheira M Int J Antimicrob Agents; 2023 Apr; 61(4):106744. PubMed ID: 36738849 [TBL] [Abstract][Full Text] [Related]
15. In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017-2020. Lee YL; Ko WC; Lee WS; Lu PL; Chen YH; Cheng SH; Lu MC; Lin CY; Wu TS; Yen MY; Wang LS; Liu CP; Shao PL; Shi ZY; Chen YS; Wang FD; Tseng SH; Lin CN; Chen YH; Sheng WH; Lee CM; Tang HJ; Hsueh PR Int J Antimicrob Agents; 2021 Sep; 58(3):106377. PubMed ID: 34166777 [TBL] [Abstract][Full Text] [Related]
16. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015. Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073 [TBL] [Abstract][Full Text] [Related]
17. Cefepime-Taniborbactam in Complicated Urinary Tract Infection. Reply. Wagenlehner FM; McGovern PC; Moeck G N Engl J Med; 2024 May; 390(20):1938-1939. PubMed ID: 38810202 [No Abstract] [Full Text] [Related]
18. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany. Seifert H; Körber-Irrgang B; Kresken M; Int J Antimicrob Agents; 2018 Feb; 51(2):227-234. PubMed ID: 28705666 [TBL] [Abstract][Full Text] [Related]
19. Cefepime-Taniborbactam in Complicated Urinary Tract Infection. Lanini S; Cai T; Tascini C N Engl J Med; 2024 May; 390(20):1937. PubMed ID: 38810199 [No Abstract] [Full Text] [Related]